ROS1 and non-small cell lung carcinoma: Similarly, shorter OS (20.3 months) in the ROS1+patients who accepted pemetrexed but without any target therapy was also observed in a study from South Korea.21 These data reflected the fact that the addition of crizotinib may contribute to the trend toward improving OS in patients with ROS1+NSCLC.